IPO Boutique

Stemline Therapeutics IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Stemline Therapeutics, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Stemline TherapeuticsSTML -
NASDAQ
$10.00-$12.00 $10.00 $11.003.3 million1/29/2013
Aegis Capital Corp
Co-Manager(s):
Feltl & Co., Sunrise Securities
Health Care
Filing(s):

Filed 2012-04-02



Stemline Therapeutics Quote & Chart - Click for current quote - STML

About Stemline Therapeutics (adapted from Stemline Therapeutics prospectus):
They are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells and tumor bulk.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "STML" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved